The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESH 2017 | The future of AML and MDS diagnosis and treatment
There is currently a conundrum regarding the differentiation of acute myeloid leukemia and myelodysplastic syndromes. In this interview, Stéphane de Botton, MD, PhD of the Gustave Roussy Institute, Villejuif, France, speaking at the International Conference on Acute Myeloid Leukaemia 2017, Estoril, Portugal by the European School of Haematology (ESH), suggests diagnosing patients based on their genotype. He also stresses the significance of new and existing treatments, including chemotherapy, broad spectrum agents and immunotherapies.
